Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
about
Antiepileptic drug monotherapy for epilepsy: a network meta-analysisUpdate on once-daily zonisamide monotherapy in partial seizuresProfile of once-daily zonisamide as monotherapy for treatment of partial seizures in adultsSeizure prognosis in brain tumors: new insights and evidence-based managementPractice Update: Review of Anticonvulsant Therapy.[New aspects in the field of epilepsy].Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.Safety and Efficacy of Zonisamide in Patients with Epilepsy: A Post-Marketing Surveillance StudyEvaluation of safety and efficacy of zonisamide in adult patients with partial, generalized, and combined seizures: an open labeled, noncomparative, observational Indian study.Long-term effect of antiepileptic drug switch on serum lipids and C-reactive proteinZonisamide: its pharmacology, efficacy and safety in clinical trials.Zonisamide in clinical practice.Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.Zonisamide: a review of its use in the management of adults with partial seizures.Development of new treatment approaches for epilepsy: unmet needs and opportunities.Zonisamide as a treatment for partial epileptic seizures: a systematic review.Pharmacotherapy of focal epilepsy.The safety and long-term efficacy of zonisamide as adjunctive therapy for focal epilepsy.Zonisamide: Review of Recent Clinical Evidence for Treatment of Epilepsy.Methodological issues associated with clinical trials in epilepsy.Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part II. Albumin-bound carbamazepine nanoparticles (ABCns).Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach.Efficacy and Tolerability of Antiepileptic Drugs in Patients with Focal Epilepsy: Systematic Review and Network Meta-analyses.Recent advances in epilepsy.Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal lobe epilepsy.Retention rate of zonisamide in intractable epilepsy.Should "historic control" epilepsy monotherapy trials be "history"?Zonisamide should be considered a first-line antiepileptic drug for patients with newly diagnosed partial epilepsy.Safety and tolerability of zonisamide in elderly patients with epilepsy.Effects of adjunctive zonisamide treatment on weight and body mass index in children with partial epilepsy.Selecting Rational Drug Combinations in Epilepsy.Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide.Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial.Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study.Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of tOff-Label Prescribing of Antiepileptic Drugs in Pharmacoresistant Epilepsy: A Cross-Sectional Drug Utilization Study of Tertiary Care Centers in Italy
P2860
Q24187678-81160F8B-1CE3-4F82-92A4-DD04CBBA805FQ26863573-997A5921-CBAB-41DE-A375-6223A6F72210Q26995736-DB656E58-4B9D-4660-9C1D-00A7E7CB525DQ33829789-735BBBF7-8A33-4771-A9E0-F1880AFB058AQ34518509-5213DF88-A316-4554-98B6-9ADB2A9BDA17Q35206626-834F8B70-5AD5-40A8-8DAC-FD0C776ACECEQ35424907-F79AADE7-63F3-45EC-B21C-A9B4D9A84AB7Q36496058-CEDDF6AC-FD64-4A00-94BD-42B2EAA56648Q36653057-B4619031-C848-4241-B78D-4FC506EF8B8BQ36923858-88604421-B29E-478B-AE06-49B5B9B0F15DQ38056166-626C6C9F-A670-4751-86BD-17DE050F4BB4Q38056168-D3142F84-0647-481F-92F8-ED78CC7587B3Q38076740-AF0FFF5F-E35A-4E03-9B32-171665444751Q38123123-91A23B0F-FA0C-4AD0-B98D-1C69F2B9CE89Q38126107-EC315897-1410-4B1E-9BF8-103E51E5F1DDQ38187589-E469FDA6-4654-4808-99A3-65FE26E87109Q38214226-A61AAAAE-0634-4353-A335-D1F3D59A5AA8Q38542947-F30CD103-58DB-4AFE-B1B8-0533E567A64AQ38553039-E53A4D8E-4111-491A-BF1F-C5208E25D801Q38656392-2E7DF9E3-676D-4318-BF13-6BAE08D45C48Q38702913-044B226D-D802-4AD5-9B74-26E26F76B2CBQ38750708-DDF140FD-ECCD-4EEC-8CDC-A853E37EDB62Q38840677-408EBD52-8602-4E55-921D-55FAB87F3F9BQ38990303-385A006F-B9E6-4D52-9015-FE735CA094DDQ39000942-C90B680B-D441-43E1-8C6B-C5C2D1AE4DD4Q40016074-AC00CBFE-C6C9-4004-982C-55350A0B5369Q41490988-016F1991-FA4F-44B2-8471-D1F2DA5270AEQ41827739-4C12447E-C770-4B3B-B827-90F316804C24Q43244034-5965718D-A7D9-41E8-8439-12270492A01CQ44037728-3A71F368-DE7E-4240-9199-0C9BC0CA55DEQ47407155-18910438-D304-4F0B-9574-A8551DEDDC00Q47869836-D4763793-CF38-4D13-93ED-99D3CCA177AAQ49292353-23169229-9B31-48C8-AD2A-7D963FAD8BA3Q50711374-038C1304-32FB-4AFB-AB61-163580B8DF26Q50787769-B81FA861-977F-4F53-A40F-ACA275B47F3CQ57543937-55D0749B-9D00-4D2C-B947-3EC5695D6666Q59222726-85596C44-4C14-4198-BC2D-98D80CA6569C
P2860
Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Efficacy and tolerability of z ...... -blind, non-inferiority trial.
@en
Efficacy and tolerability of z ...... -blind, non-inferiority trial.
@nl
type
label
Efficacy and tolerability of z ...... -blind, non-inferiority trial.
@en
Efficacy and tolerability of z ...... -blind, non-inferiority trial.
@nl
prefLabel
Efficacy and tolerability of z ...... -blind, non-inferiority trial.
@en
Efficacy and tolerability of z ...... -blind, non-inferiority trial.
@nl
P2093
P1433
P1476
Efficacy and tolerability of z ...... -blind, non-inferiority trial.
@en
P2093
Anna Patten
Joanna Segieth
Luigi Giorgi
Martin J Brodie
Michel Baulac
P304
P356
10.1016/S1474-4422(12)70105-9
P577
2012-06-08T00:00:00Z